CoChat
Sign Up
Cited by 12

The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.

Microglia targeting by adeno-associated viral vectors

Stamataki, Maria, Rissiek, Björn, Magnus, Tim, Körbelin, Jakob·2024·Frontiers in Immunology
DOI 10.3389/fimmu.2024.1425892PMC PMC11257843
Open this paper in CoChat — free account

Abstract

Microglia play a crucial role in maintaining homeostasis of the central nervous system and they are actively involved in shaping the brain’s inflammatory response to stress. Among the multitude of involved molecules, purinergic receptors and enzymes are of special importance due to their ability to regulate microglia activation. By investigating the mechanisms underlying microglial responses and dysregulation, researchers can develop more precise interventions to modulate microglial behavior and alleviate neuroinflammatory processes. Studying gene function selectively in microglia, however, remains technically challenging. This review article provides an overview of adeno-associated virus (AAV)-based microglia targeting approaches, discussing potential prospects for refining these approaches to improve both specificity and effectiveness and encouraging future investigations aimed at connecting the potential of AAV-mediated microglial targeting for therapeutic benefit in neurological disorders.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3389/fimmu.2024.1425892

Cites

9 of 9 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 AAV-based microglia targeting approaches. Overview of AAV vectors that have successfully been used to transduce microglia. (A) AAV6 and AAV8 were shown to efficiently transduce primary microglia in vitro when employing the ubiquitous CMV promoter (18), while the AAV6 capsid mutant AAV TM6 in combination with the F4/80 or CD68 promoter showed specificity for microglia upon incubation with primary microglia, astrocytes and mixed neuroglia (19). (B) The AAV6 capsid mutants AAV TM6 and AAV6Δ4 showed successful microglia transduction in vivo upon intravitreal and subretinal injection when employing the CD68 promoter (21). AAV8 in combination with the ubiquitous CAG promoter was shown to transduce microglia upon intravitreal injection (20). (C) AAV5, AAV TM6, AAV8, AAV9 and the AAV9 peptide-displaying variants MG1.1 and MG1.2 successfully transduced microglia upon intraparenchymal brain injection while assessing transgene (mScarlet) expression by inducible vectors in cre-positive mice (24). AAV9-mediated microglia-specific transgene expression upon intraparenchymal brain injection was further enhanced by employing the Iba1 promoter and targeting elements for miR-9 and miR-129-23 in four copies each (16). (D) The AAV9 peptide-displaying variants ALAVPFR, ALAVPFK, HGTAASH, and YAFGGEG were recently shown to transduce microglia and macrophages with high efficiently even upon intravenous injection in mice. Gene expression was accomplished by employing the CD11b promoter (25). This figure was generated with Biorender.com.
Figure 1 AAV-based microglia targeting approaches. Overview of AAV vectors that have successfully been used to transduce microglia. (A) AAV6 and AAV8 were shown to efficiently transduce primary microglia in vitro when employing the ubiquitous CMV promoter (18), while the AAV6 capsid mutant AAV TM6 in combination with the F4/80 or CD68 promoter showed specificity for microglia upon incubation with primary microglia, astrocytes and mixed neuroglia (19). (B) The AAV6 capsid mutants AAV TM6 and AAV6Δ4 showed successful microglia transduction in vivo upon intravitreal and subretinal injection when employing the CD68 promoter (21). AAV8 in combination with the ubiquitous CAG promoter was shown to transduce microglia upon intravitreal injection (20). (C) AAV5, AAV TM6, AAV8, AAV9 and the AAV9 peptide-displaying variants MG1.1 and MG1.2 successfully transduced microglia upon intraparenchymal brain injection while assessing transgene (mScarlet) expression by inducible vectors in cre-positive mice (24). AAV9-mediated microglia-specific transgene expression upon intraparenchymal brain injection was further enhanced by employing the Iba1 promoter and targeting elements for miR-9 and miR-129-23 in four copies each (16). (D) The AAV9 peptide-displaying variants ALAVPFR, ALAVPFK, HGTAASH, and YAFGGEG were recently shown to transduce microglia and macrophages with high efficiently even upon intravenous injection in mice. Gene expression was accomplished by employing the CD11b promoter (25). This figure was generated with Biorender.com.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 9 references

Research works printed but not linked: 30

  1. Woodburn, 2021, The semantics of microglia activation: neuroinflammation, homeostasis, and stress, J Neuroinflamm, 18, 258, 10.1186/s12974-021-02309-6 · DOI · Paper page
  2. Monif, 2009, The P2X7 receptor drives microglial activation and proliferation: a trophic role for P2X7R pore, J Neurosci, 29, 10.1523/JNEUROSCI.5512-08.2009 · DOI · Paper page
  3. Pinto-Espinoza, 2022, Effective targeting of microglial P2X7 following intracerebroventricular delivery of nanobodies and nanobody-encoding AAVs, Front Pharmacol, 13, 10.3389/fphar.2022.1029236 · DOI
  4. Hickman, 2013, The microglial sensome revealed by direct RNA sequencing, Nat Neurosci, 16, 10.1038/nn.3554 · DOI · Paper page
  5. Wang, 2015, Role of pro-inflammatory cytokines released from microglia in Alzheimer's disease, Ann Transl Med, 3, 136, 10.3978/j.issn.2305-5839.2015.03.49 · DOI
  6. Arbeloa, 2012, P2X7 receptor blockade prevents ATP excitotoxicity in neurons and reduces brain damage after ischemia, Neurobiol Dis, 45, 10.1016/j.nbd.2011.12.014 · DOI
  7. Cisneros-Mejorado, 2015, Blockade of P2X7 receptors or pannexin-1 channels similarly attenuates postischemic damage, J Cereb Blood Flow Metab, 35, 10.1038/jcbfm.2014.262 · DOI
  8. Lee, 2011, Microglial P2X(7) receptor expression is accompanied by neuronal damage in the cerebral cortex of the APPswe/PS1dE9 mouse model of Alzheimer's disease, Exp Mol Med, 43, 7, 10.3858/emm.2011.43.1.001 · DOI
  9. Kang, 2023, AAV vectors applied to the treatment of CNS disorders: Clinical status and challenges, J Control Release, 355, 10.1016/j.jconrel.2023.01.067 · DOI · Paper page
  10. Riyad, 2021, Intracellular trafficking of adeno-associated virus (AAV) vectors: challenges and future directions, Gene Ther, 28, 10.1038/s41434-021-00243-z · DOI
  11. Shah, 2022, Microglia-specific promoter activities of HEXB gene, Front Cell Neurosci, 16, 10.3389/fncel.2022.808598 · DOI
  12. Okada, 2022, Development of microglia-targeting adeno-associated viral vectors as tools to study microglial behavior in vivo, Commun Biol, 5, 1224, 10.1038/s42003-022-04200-3 · DOI · Paper page
  13. Merlin, 2019, Transcriptional targeting and microRNA regulation of lentiviral vectors, Mol Ther Methods Clin Dev, 12, 10.1016/j.omtm.2018.12.013 · DOI
  14. Su, 2016, Recombinant adeno-associated viral (rAAV) vectors mediate efficient gene transduction in cultured neonatal and adult microglia, J Neurochem, 49, 10.1111/jnc.13081 · DOI
  15. Rosario, 2016, Microglia-specific targeting by novel capsid-modified AAV6 vectors, Mol Ther Methods Clin Dev, 3, 16026, 10.1038/mtm.2016.26 · DOI
  16. Maes, 2021, Optimizing AAV2/6 microglial targeting identified enhanced efficiency in the photoreceptor degenerative environment, Mol Ther Methods Clin Dev, 23, 10.1016/j.omtm.2021.09.006 · DOI
  17. Langer, 2023, Intravitreal AAV delivery causes long-term subclinical microglia activation in mice, Invest Ophthalmol Visual Sci, 64
  18. John, 2023, Gene therapy-associated retinal inflammation may arise from AAV transduction of resident microglia, Invest Ophthalmol Visual Sci, 64
  19. Young, 2023, Targeted evolution of adeno-associated virus capsids for systemic transgene delivery to microglia and tissue-resident macrophages, Proc Natl Acad Sci U.S.A, 120, 10.1073/pnas.2302997120 · DOI
  20. Pandya, 2014, Rationally designed capsid and transgene cassette of AAV6 vectors for dendritic cell-based cancer immunotherapy, Immunol Cell Biol, 92, 10.1038/icb.2013.74 · DOI
  21. Korbelin, 2016, A brain microvasculature endothelial cell-specific viral vector with the potential to treat neurovascular and neurological diseases, EMBO Mol Med, 8, 10.15252/emmm.201506078 · DOI
  22. Korbelin, 2016, Pulmonary targeting of adeno-associated viral vectors by next-generation sequencing-guided screening of random capsid displayed peptide libraries, Mol Ther, 24, 10.1038/mt.2016.62 · DOI
  23. Liguore, 2019, AAV-PHP.B administration results in a differential pattern of CNS biodistribution in non-human primates compared with mice, Mol Ther, 27, 10.1016/j.ymthe.2019.07.017 · DOI
  24. Krolak, 2022, A high-efficiency AAV for endothelial cell transduction throughout the central nervous system, Nat Cardiovasc Res, 1, 389, 10.1038/s44161-022-00046-4 · DOI
  25. Goertsen, 2022, Targeting the lung epithelium after intravenous delivery by directed evolution of underexplored sites on the AAV capsid, Mol Ther Methods Clin Dev, 26, 10.1016/j.omtm.2022.07.010 · DOI
  26. Mathiesen, 2020, CNS transduction benefits of AAV-PHP.eB over AAV9 are dependent on administration route and mouse strain, Mol Ther Methods Clin Dev, 19, 10.1016/j.omtm.2020.10.011 · DOI
  27. Shen, 2012, Glycan binding avidity determines the systemic fate of adeno-associated virus type 9, J Virol, 86, 10.1128/JVI.01155-12 · DOI
  28. Eichhoff, 2019, Nanobody-enhanced targeting of AAV gene therapy vectors, Mol Ther Methods Clin Dev, 15, 10.1016/j.omtm.2019.09.003 · DOI
  29. Matsuzaki, 2018, Intravenous administration of the adeno-associated virus-PHP.B capsid fails to upregulate transduction efficiency in the marmoset brain, Neurosci Lett, 665, 10.1016/j.neulet.2017.11.049 · DOI · Paper page
  30. Kremer, 2024, AAV-BR1 does not target endothelial cells in Sprague Dawley rats unlike in mice, MicroPubl Biol, 2024, 10.17912/micropub.biology.001120 · DOI

Cited by

Sorted by citations

Metadata

Authors
Stamataki, M., Rissiek, B., Magnus, T., & Körbelin, J.
Venue
Frontiers in Immunology
Publisher
Frontiers Media SA
Published
2024-07-05
Volume
15
ISSN
1664-3224
DOI
10.3389/fimmu.2024.1425892
PMC
PMC11257843
Cited by
12
References
9
Licence
creativecommons.org/licenses/by/4.0/ (vor)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review